2021.12.10
On December 10, 2021, Asymchem Laboratories (Tianjin) Co., Ltd. ("Asymchem") issued 18,415,400 H-shares worldwide (before exercising the over-allotment options) and listed on the main board of the Hong Kong Stock Exchange with the stock code: 6821.HK. The issue price was HK $388 per share and approximately HK$ 6,850 million net proceeds were raised (before exercising the over-allotment options). This was the largest medical IPO project in Hong Kong's capital market in 2021.
Asymchem is a global leading contract development manufacturing organization (CDMO), serving the global pharmaceutical industry. It provides R&D and one-stop production services to the world’s top pharmaceutical companies. Asymchem’s business ranges from the early clinical stage to the commercial stage and includes R&D and CGMP production of advanced intermediates, APIs and formulations, as well as clinical research services. With more than 20 years of development in the field of CDMO, Asymchem is in a leading global position in the fields of continuous chemistry and biocatalysis and has become a long-term partner of the world's leading and best-known pharmaceutical enterprises. In terms of revenue in 2020, Asymchem was the fifth largest CDMO of API in the world and the largest chemical drug CDMO at the stage of commercialization headquartered in China. Asymchem is an A-share listed company and is listed on the Shenzhen Stock Exchange (Stock Code: 002821). This H-share listing will realize its A+H Listing.
Ashymchem planned to first launch its H-share listing project in 2018, then suspended it for various reasons and restarted it again in 2021. JunHe acted as the PRC legal counsel for the co-sponsor in the project, addressing the negative effects of the COVID-19 pandemic and other factors. The team provided high-quality, prudent and efficient legal services which included conducting legal due diligence and reviewing and revising the prospectus as well as the application and issuance documents related to the IPO. JunHe issued PRC legal opinions, assisted the sponsor in actively responding to the PRC legal compliance concerns raised by the CSRC and the SEHK., and finally obtained the full approval of the regulatory authorities. JunHe's team was highly recognized by the client and the other intermediaries for its working attitude and professional expertise.
The leading partner was Mr. ZHANG, Tao. The main contractor partner was Ms. YE, Junli and the partner for the internal review was Mr. ZHOU, Fang.
